TELA Bio, Inc. reported its financial results for the third quarter of 2026, revealing a significant reduction in operating losses and an increase in international revenue. The company’s performance is noteworthy as it navigates the challenges of the surgical and medical instruments industry.

On November 10, 2026, TELA Bio, Inc. (NASDAQ: TELA) announced its financial results for the third quarter ended September 30, 2026. The results are significant as they highlight the company's ongoing efforts to stabilize and grow in a competitive market.

Background

TELA Bio, Inc., incorporated in Delaware, operates in the surgical and medical instruments and apparatus sector (SIC: 3841). The company focuses on innovative soft-tissue reconstruction solutions and has been listed on the Nasdaq under the ticker symbol TELA. Recent filings include a 10-Q and an S-3, both filed on November 10, 2026, along with this 8-K.

What the Filing Says

The filing reveals that TELA Bio delivered $19.0 million in revenue during the third quarter, a decrease from $20.7 million in the same quarter of the previous year. However, the company reported a 21% reduction in sequential operating losses, dropping from $9.3 million to $7.3 million. Adjusted EBITDA loss also improved significantly, decreasing by 55% sequentially.

“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway,” said Heather Getz, CEO of TELA Bio.

Additionally, TELA Bio has announced a strategic cost reduction initiative aimed at decreasing annual operating expenses by $17.0 million, which will help extend its cash runway into 2028. The company regained compliance with Nasdaq's minimum bid price requirement, a crucial step for maintaining its listing.

Impact

This financial update is likely to affect TELA Bio's investors and stakeholders, particularly as the company demonstrates a commitment to improving its financial health. The surgical and medical instruments sector may see increased competition as TELA positions itself for growth, especially with its innovative offerings like the OviTex product line.

What's Next

The filing does not specify what happens next, but TELA Bio is expected to continue executing its strategic initiatives and may provide further updates in future filings or press releases.